Compass points to positive psilocybin trial, but shares fallCompass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was Share XCompass points to positive psilocybin trial, but shares fallhttps://pharmaphorum.com/news/compass-points-to-positive-psilocybin-trial-but-shares-fall/
Biogen, Sage prep 2022 filing for depression drug zuranoloneThe renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to Share XBiogen, Sage prep 2022 filing for depression drug zuranolonehttps://pharmaphorum.com/news/biogen-sage-prep-2022-filing-for-depression-drug-zuranolone/
First subject dosed in psilocybin trial for rare headache disorderThe first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial Share XFirst subject dosed in psilocybin trial for rare headache disorderhttps://pharmaphorum.com/news/first-subject-dosed-in-psilocybin-trial-for-rare-headache-disorder/
FDA clears J&J’s twice-yearly Invega for schizophreniaOne of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Share XFDA clears J&J’s twice-yearly Invega for schizophreniahttps://pharmaphorum.com/news/fda-clears-jjs-twice-yearly-invega-for-schizophrenia/
Beckley Psytech raises $80m for psychedelic meds developmentUK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed Share XBeckley Psytech raises $80m for psychedelic meds developmenthttps://pharmaphorum.com/news/beckley-psytech-raises-80m-for-psychedelic-meds-development/
Predicting and improving clinical trial enrolment: A problem for psychiatryPatient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a Share XPredicting and improving clinical trial enrolment: A problem for psychiatryhttps://pharmaphorum.com/views-and-analysis/predicting-and-improving-clinical-trial-enrolment-a-problem-for-psychiatry/
Sage/Biogen’s zuranolone works in depression, but maybe not enoughSage Therapeutics and Biogen’s antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a Share XSage/Biogen’s zuranolone works in depression, but maybe not enoughhttps://pharmaphorum.com/news/sage-biogens-zuranolone-works-in-depression-but-maybe-not-enough/
Aduhelm approval could signal new era for CNS drugs; analystsThe unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the Share XAduhelm approval could signal new era for CNS drugs; analystshttps://pharmaphorum.com/news/aduhelm-approval-could-signal-new-era-for-cns-drugs-analysts/
Study finds “alarming” hike in antidepressant costs during COVID-19Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in Share XStudy finds “alarming” hike in antidepressant costs during COVID-19https://pharmaphorum.com/news/study-finds-alarming-hike-in-antidepressant-costs-during-covid-19/
